BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial.

MLA

Wang, Weijia, et al. “BCMA-CD19 Compound CAR T Cells for Systemic Lupus Erythematosus: A Phase 1 Open-Label Clinical Trial.” Annals of the Rheumatic Diseases, vol. 83, no. 10, Sept. 2024, pp. 1304–14. EBSCOhost, https://doi.org/10.1136/ard-2024-225785.

APA

Wang, W., He, S., Zhang, W., Zhang, H., DeStefano, V. M., Wada, M., Pinz, K., Deener, G., Shah, D., Hagag, N., Wang, M., Hong, M., Zeng, R., Lan, T., Ma, Y., Li, F., Liang, Y., Guo, Z., Zou, C., … Yuan, Y. (2024). BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Annals of the Rheumatic Diseases, 83(10), 1304–1314. https://doi.org/10.1136/ard-2024-225785

Chicago

Wang, Weijia, Shanzhi He, Wenli Zhang, Hongyu Zhang, Vincent M DeStefano, Masayuki Wada, Kevin Pinz, et al. 2024. “BCMA-CD19 Compound CAR T Cells for Systemic Lupus Erythematosus: A Phase 1 Open-Label Clinical Trial.” Annals of the Rheumatic Diseases 83 (10): 1304–14. doi:10.1136/ard-2024-225785.